Dinaciclib, however, was selected to be the drug of choice for CDC20 in this study as it has never been reported for CCA, and the safety and efficacy has been reported in the clinical trial phase III (Ghia et al., 2015; Sharp & Corp, 2017). The gene discussed is CDC20; the disease is cholangiocarcinoma.